Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Guzman, Carlos ABorsutzky, Stefan
Griot-Wenk, Monika
Metcalfe, Ian C
Pearman, Jon
Collioud, Andre
Favre, Didier
Dietrich, Guido
Issue Date
2006-05-01
Metadata
Show full item recordAbstract
Because of high infectivity and significant disease burden, typhoid fever constitutes a major global health problem. Implementation of adequate food handling practices and establishment of safe water supplies are the cornerstone for the development of an effective prevention program. However, vaccination against typhoid fever remains an essential tool for the effective management of this disease. Currently, there are two well tolerated and effective licensed vaccines. One is based on defined subunit virulence (Vi) polysaccharide antigen and can be administered either intramuscularly or subcutaneously and the other is based on the use of live attenuated bacteria for oral administration. The advantages and disadvantages of the various approaches taken in the development of a vaccine against typhoid fever are discussed, along with the potential for future vaccine candidates.Citation
Vaccines against typhoid fever. 2006, 24 (18):3804-11 VaccineAffiliation
Vaccine Research Group, Division of Microbiology, GBF-German Research Centre for Biotechnology, Mascheroder Weg 1, Braunschweig, Germany.Journal
VaccinePubMed ID
16278037Type
ArticleLanguage
enISSN
0264-410Xae974a485f413a2113503eed53cd6c53
10.1016/j.vaccine.2005.07.111
Scopus Count
Related articles
- Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
- Authors: Pakkanen SH, Kantele JM, Savolainen LE, Rombo L, Kantele A
- Issue date: 2015 Jan 9
- Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi.
- Authors: Xiong K, Zhu C, Chen Z, Zheng C, Tan Y, Rao X, Cong Y
- Issue date: 2017
- Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination.
- Authors: Pakkanen SH, Kantele JM, Kantele A
- Issue date: 2012 Sep 14
- A review of the current status of enteric vaccines.
- Authors: Levine MM, Noriega F
- Issue date: 1995 Dec
- Re: typhoid fever vaccines: systematic review and meta-analysis of randomised clinical trials.
- Authors: Arya SC, Agarwal N
- Issue date: 2008 Jan 17